Navigation Links
First Implant of DuraHeart(TM) Left Ventricular Assist System (LVAS) in Japanese Clinical Trial
Date:10/31/2008

ANN ARBOR, Mich., Oct. 31 /PRNewswire/ -- Terumo Heart Inc. announced that the first DuraHeart(TM) Left Ventricular Assist System (LVAS) was implanted in October at the University of Tokyo Hospital in Japan. Terumo Corporation will continue efforts toward an early application for approval for manufacture and sales in Japan.

Terumo's LVAS is the world's first third generation left ventricular assist system combining a centrifugal pump with a magnetically levitated impeller. The product received the CE mark in Europe in 2007 and began its U.S. Pivotal Trial in July 2008.

The "Mag-Lev" centrifugal pump technology was developed by Dr. Akamatsu, former professor of the Faculty of Engineering, Kyoto University in collaboration with NTN Corporation. The development base was moved to the U.S. in 2000 to continue product realization and commercialization.

In Japan, the Ministry of Health, Labor and Welfare highlighted implantable left ventricular assist devices in the "Council Regarding Early Introduction of Medical Equipment with Medical Needs."

Terumo Heart, Inc. is a U.S. subsidiary of Terumo Corporation with headquarters and manufacturing facilities in Ann Arbor, Michigan. The company's focus is the innovation and introduction of products to improve the quality of healthcare for heart failure patients. Terumo Corporation, located in Tokyo, Japan, is a leading developer, manufacturer and global marketer of a wide array of medical products. DuraHeart is limited to investigational use only in the United States, and is CE marked in Europe.


'/>"/>
SOURCE Terumo Heart, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. The First Years True Fit C630 Convertible Car Seat Recieves Highest Given Rating From the National Highway Traffic Safety Administration
2. First evidence that prenatal exposure to famine may lead to persistent epigenetic changes
3. Obama Puts Healthcare, Economic Relief for Middle Class First in Prime-Time Special
4. WPI receives award from Homeland Security Department to advance first-responder location
5. First Results from Hospital Trials Show Pathogens Stay Close to Patients
6. NovoLogix Launches First Annual Symposium for Healthcare Thought Leaders
7. Dr. Henry Barnett becomes first person outside Europe to receive Karolinska Stroke Award
8. Evolution Physical Therapy First Clinic in Southern California to Introduce NASA-Designed Anti-Gravity Treadmill for Public Use
9. Fight begins to eradicate fatal parasite; first vaccines delivered following major funding award
10. Mylans Matrix First-to-File on Generic Version of Vfend(R) Antifungal
11. P&G Reports First Quarter EPS of $1.03 Up 12% on 9% Sales Growth
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:LCA-Vision's National Lasik Network Named as U.S. Provider for National Vision Administrators 2Health News:LCA-Vision's National Lasik Network Named as U.S. Provider for National Vision Administrators 3Health News:LCA-Vision's National Lasik Network Named as U.S. Provider for National Vision Administrators 4Health News:WuXi AppTec Successfully Holds Its 2009 Supplier Conference in Shanghai 2Health News:WuXi AppTec Successfully Holds Its 2009 Supplier Conference in Shanghai 3Health News:New Occupational Therapy School and Career Resource on All Allied Health Schools 2Health News:New Occupational Therapy School and Career Resource on All Allied Health Schools 3Health News:Compass Pharma Services Offers Microfill Capabilities to Contract Pharmaceutical Packaging Customers 2Health News:Helping to Clear the Air for Consumers - New Certification Standard for HEPA Filters Will Help Millions of People Make More Educated Choices 2Health News:Official Launch of ABLE TO CHOOSE Public Awareness Campaign 2
Breaking Medicine Technology:FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10Senator Durbin Leads Fight to Protect Americas Kids from Tobacco 48681 1Senator Durbin Leads Fight to Protect Americas Kids from Tobacco 48681 2Senator Durbin Leads Fight to Protect Americas Kids from Tobacco 48681 3Herley Industries Inc Reports Third Quarter Earnings 48677 1Herley Industries Inc Reports Third Quarter Earnings 48677 2Herley Industries Inc Reports Third Quarter Earnings 48677 3Herley Industries Inc Reports Third Quarter Earnings 48677 4Herley Industries Inc Reports Third Quarter Earnings 48677 5Herley Industries Inc Reports Third Quarter Earnings 48677 6Herley Industries Inc Reports Third Quarter Earnings 48677 7Herley Industries Inc Reports Third Quarter Earnings 48677 8Herley Industries Inc Reports Third Quarter Earnings 48677 9Herley Industries Inc Reports Third Quarter Earnings 48677 10Herley Industries Inc Reports Third Quarter Earnings 48677 11Herley Industries Inc Reports Third Quarter Earnings 48677 12Bionovo Announces Arbitration Decision in Lawsuit Filed by Former Officer All Claims Denied 48673 1Bionovo Announces Arbitration Decision in Lawsuit Filed by Former Officer All Claims Denied 48673 2